- Open Access
Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy
© Ilk et al; licensee BioMed Central Ltd. 2011
- Received: 27 October 2010
- Accepted: 10 February 2011
- Published: 10 February 2011
Genetic fusion of the major birch pollen allergen (Bet v1) to bacterial surface-(S)-layer proteins resulted in recombinant proteins exhibiting reduced allergenicity as well as immunomodulatory capacity. Thus, S-layer/allergen fusion proteins were considered as suitable carriers for new immunotherapeutical vaccines for treatment of Type I hypersensitivity. Up to now, endotoxin contamination of the fusion protein which occurred after isolation from the gram-negative expression host E. coli had to be removed by an expensive and time consuming procedure. In the present study, in order to achieve expression of pyrogen-free, recombinant S-layer/allergen fusion protein and to study the secretion of a protein capable to self-assemble, the S-layer/allergen fusion protein rSbpA/Bet v1 was produced in the gram-positive organism Bacillus subtilis 1012.
The chimaeric gene encoding the S-layer protein SbpA of Lysinibacillus sphaericus CCM 2177 as well as Bet v1 was cloned and expressed in B. subtilis 1012. For that purpose, the E. coli-B. subtilis shuttle vectors pHT01 for expression in the B. subtilis cytoplasm and pHT43 for secretion of the recombinant fusion protein into the culture medium were used. As shown by western blot analysis, immediately after induction of expression, B. subtilis 1012 was able to secret rSbpA/Bet v1 mediated by the signal peptide amyQ of Bacillus amyloliquefaciens. Electron microscopical investigation of the culture medium revealed that the secreted fusion protein was able to form self-assembly products in suspension but did not recrystallize on the surface of the B. subtilis cells. The specific binding mechanism between the N-terminus of the S-layer protein and a secondary cell wall polymer (SCWP), located in the peptidoglycan-containing sacculi of Ly. sphaericus CCM 2177, could be used for isolation and purification of the secreted fusion protein from the culture medium. Immune reactivity of rSbpA/Bet v1 could be demonstrated in immunoblotting experiments with Bet v1 specific IgE containing serum samples from patients suffering birch pollen allergy.
The impact of this study can be seen in the usage of a gram-positive organism for the production of pyrogen-free self-assembling recombinant S-layer/allergen fusion protein with great relevance for the development of vaccines for immunotherapy of atopic allergy.
- Fusion Protein
- Electron Microscopical Investigation
- Birch Pollen
- Cell Wall Fragment
- Chimaeric Gene
S-layers are crystalline arrays of proteinaceous subunits representing the outermost cell envelope component in many bacteria and most archaea [1–3]. One of the most remarkable properties of isolated S-layer proteins is their capability to self-assemble in suspension as flat sheets or cylinders, into monomolecular protein lattices on artificial surfaces (e. g. silicon wafers, noble metals, plastics) or on Langmuir lipid films and liposomes [4–6]. S-layer proteins from Bacillaceae specifically recognize a distinct type of secondary cell wall polymer (SCWP) as the proper anchoring structure in the rigid cell wall layer [7–10]. The SCWP of Ly. sphaericus CCM 2177 consists of disaccharide repeating units that are composed of N-acetyl glucosamine (GlcNAc) and N-acetyl mannosamine (ManNAc). The ManNAc residues carry a pyruvate ketal which endows the polymer chains with a negative net charge . In previous studies, isolated S-layer-specific SCWP was also used as biomimetic linker for the oriented recrystallization of recombinant S-layer fusion proteins incorporating foreign functional sequences, such as antigens, antibodies, ligands, or enzymes on solid supports [5, 6].
Due to the intrinsic adjuvant ability of S-layers as well as their capability to display proteins and epitopes on their surface, S-layers are excellent candidates to be used as antigen carriers . Specific immunotherapy (SIT), a method consisting of the consecutive injection of increasing doses of specific allergen to induce specific tolerance in the allergic patient, represent the only causative treatment for Type I allergy . Attempts to improve vaccines for SIT focused on the allergic molecules as well as on adjuvants that support the shift of the Th2-based immune response toward a more balanced phenotype . For this purpose, in recent studies, the gene sequence encoding the major birch pollen allergen Bet v1, was fused with the genes encoding the S-layer protein of Geobacillus stearothermophilus ATCC 12980 or Lysinibacillus sphaericus CCM 2177 resulting in the recombinant fusion proteins rSbsC/Bet v1 or rSbpA/Bet v1, respectively [14, 15]. Both S-layer/allergen fusion proteins contained all relevant Bet v1-specific B and T cell epitopes, but were significantly less efficient to release histamine than rBet v1 [13, 16, 17]. Further immunological studies showed that both fusion proteins displayed strongly reduced IgE binding capacity than free rBet v1 and promoted the induction of allergen-specific Th0/1 cells and regulatory T cells [13, 16, 17]. Derived from these results, both recombinant S-layer/allergen fusion proteins can be considered as promising candidates for the development of vaccines for specific immunotherapy of Type I allergies.
In previous studies, gram-negative E. coli was used for heterologous expression of rSbsC/Bet v1 or rSbpA/Bet v1, respectively. Moreover, a very material and time consuming purification procedure was performed to remove endotoxin which was associated with the isolated S-layer/allergen fusion proteins [14, 15]. In immunological applications, the presence of small amounts of endotoxins, also called lipopolysaccharides (LPS), co-purified with recombinant protein can cause fever, tissue injury, endotoxin shock syndrome or the activation of non-specific immune response in macrophages or B cells . Due to the fact that endotoxin removal techniques belong to the most difficult tasks in downstream processes during protein purification, the establishment of a gram-positive endotoxin-free expression system for S-layer/allergen fusion proteins was required.
The choice of an appropriate host and suitable production conditions is crucial for the downstream processing of a pharmaceutical-grade product . In contrast to the gram-negative E. coli, B. subtilis is considered as a GRAS (generally recognized as safe) organism . The reason for the usage of B. subtilis as cell factory for the production of proteins with biotechnological application potential, are a) its ability to secrete functional extracellular proteins directly to the culture medium and b) the accumulation of information concerning its transcription and translation mechanisms, genetic manipulation and large scale fermentation which has been acquired during the last years . A further advantage for expression of recombinant S-layer/allergen fusion proteins can be seen in the fact that B. subtilis strains carry no S-layer on their cell surface.
In the present study, the strain B. subtilis 1012, a non-pathogenic organism with naturally high secretory capacity was used as host for expression of the recombinant S-layer/allergen fusion protein rSbpA/Bet v1. E. coli - B. subtilis shuttle vectors pHT01, for intracellular expression, and pHT43, carrying the coding region for the signal peptide of the amyQ gene encoding a Bacillus amyloliquefaciens α-amylase fused to the Shine-Dalgarno sequence for extracelluar expression, were chosen.
Construction of E. coli-B. subtilis shuttle vectors pHT01 and pHT43 carrying the chimaeric gene encoding the S-layer/allergen fusion protein rSbpA/Bet v1 as well as transformation of B. subtilis 1012
The E. coli-B. subtilis shuttle vectors pHT01 and pHT43 allow expression of recombinant proteins within the cytoplasm, where pHT43 directs the target protein into the medium. Both vectors are based on the σA-dependent promoter preceding the groE operon of B. subtilis which has been converted into an IPTG-inducible promoter by addition of the lac operator. For construction of the B. subtilis expression vectors, the chimaeric gene sbpA/bet v1 was cloned into the cloning sites Aat II and Sma I of plasmid pHT01 or pHT43, respectively.
Intracellular and extracellular expression of the S-layer/allergen fusion protein rSbpA/Bet v1 by B. subtilis 1012 and immunoblot analysis
Investigation of intracellular expression of rSbpA/Bet v1 by B. subtilis 1012 carrying pHT01/sbpA/bet v1 done by immunoblotting of SDS-extracted cell pellets with anti-SbpA antiserum (Figure 2B, lanes 2-4) or BIP1 (Figure 2B, lane 6) showed only a faint protein band of 127.5 kDa. Extension of expression time until over night did not result in higher yield of rSbpA/Bet v1 (data not shown). No S-layer fusion protein could be found before induction of expression (Figure 2B, lanes 1 and 5) or in the culture supernatant (data not shown). By comparing the growth curves of induced and non-induced B. subtilis cells carrying pHT43/sbpA/bet v1 and pHT01/sbpA/bet v1, respectively, it could be demonstrated that expression of rSbpA/Bet v1 did not affect growth of B. subtilis (data not shown).
TEM analysis of B. subtilis 1012 cells after expression and secretion of the S-layer/allergen fusion protein rSbpA/Bet v1
Recrystallization of the S-layer/allergen fusion protein on solid supports, immunogold-labelling and electron microscopical investigation
Quantification of the amount of purified rSbpA/Bet v1 after extracelluar expression by B. subtilis 1012
Reaction of rSbpA/Bet v1 with Bet v1 specific IgE on immunoblots
Biocompatibility tests for investigation of Limulus amebocyte lyste (LAL) reactivity of rSbpA/Bet v1 expressed in B. subtilis 1012 compared to the S-layer/allergen fusion protein expressed in E. coli
LAL reactivity of rSbpA/Bet v1 expressed in gram-positive B. subtilis 1012 was tested and compared to the endotoxin contamination of the recombinant S-layer/allergen fusion protein isolated from gram-negative E. coli. LAL assays revealed a LPS value of 20 EU/ml for rSbpA/Bet v1 after intracellular expression in E. coli, isolation from the host cell and purification with gel permeation chromatography (GPC) as well as an endotoxin value of 1-2 EU/ml after a second GPC purification step. In contrast to these results, no endotoxin could be detected in rSbpA/Bet v1 expressed by B. subtilis 1012 and secreted into the culture medium.
Because of their temperature and pH stability, the removal of bacterial endotoxins becomes more difficult when associated with labile biomolecules, such as proteins . Besides commonly used techniques like for example ultrafiltration  and ion exchange chromatography , affinity chromatography is reported as an effective method to reduce endotoxin in solutions . Ultrafiltration can be useful to remove endotoxin aggregates  but with large proteins like rSbpA/Bet v1 with a molecular weight of 127.5 kDa, used in this study, this method is not effective. Due to the fact, that S-layers are insoluble in buffers usually taken for affinity chromatography, this technique turned out to be unsuitable for endotoxin removal from S-layer preparations. To achieve complete solubilization of S-layer proteins into their constituent subunits, the addition of high concentrated hydrogen-bond-breaking agents (e. g. urea, guanidinium hydrochloride) is required [5, 6, 26].
In recent years, various studies revealed that non-pathogenic gram-positive B. subtilis is an attractive host organism for the expression and secretion of heterologous proteins [19, 21, 27]. The advantage of secretion of the target protein can be seen in a natural separation of the product from cell components simplifying downstream processing as well as in the provision of better refolding conditions compared to the reducing conditions in the cell cytoplasm .
In the present study, with the aim to produce an endotoxin-free S-layer/allergen fusion protein, a gram-positive expression system was developed based on the expression host B. subtilis 1012 as well as the E. coli-B. subtilis shuttle vectors pHT01 or pHT43 carrying the amyQ signal sequence. To estimate the point in time for development of maximal natural competence, the growth curve of B. subtilis 1012 was recorded and culture aliquots of estimated maximal competence were used for transformation with the plasmids carrying a chimaeric gene encoding rSbpA/Bet v1. In the case of B. subtilis 1012 cells carrying pHT43/sbpA/bet v1, comparison of the amount of rSbpA/Bet v1 in whole cells and in the supernatant by SDS-PAGE revealed that the main part of the produced fusion protein was secreted into the culture medium from the beginning to the end of the stationary growth phase. From these results, it can be concluded that the signal peptide of the B. subtilis α-amylase works well for S-layer fusion proteins and the high molecular weight of the target protein did not interfere with the secretion process. Additionally, it could be demonstrated that the growth rate of B. subtilis was not affected by the induction of rsbpA/bet v1 expression.
In , Howorka and co-workers reported the self-assembly formation of SbsA, the S-layer protein of G. stearothermophilus PV72/p6 in the course of autolysis after expression in B. subtilis. This expression system based on the xylose-inducible multicopy plasmid pSTR5 carrying the sbsA gene as well as the signal peptide of the S-layer protein SbsA showed high level intracellular expression but rSbsA was retained in the B. subtilis peptidoglycan layer and therefore was poorly secreted into the ambient cellular environment. In former studies concerning the heterologous expression in E. coli, it could be demonstrated that the recombinant S-layer proteins SbsA of G. stearothermophilus PV72/p6, SbsB of G. stearothermophilus PV72/p2 or SbsC from G. stearothermophilus ATCC 12980, respectively, formed self-assembly products in the cell cytoplasm directly after expression [29–31]. In contrast to these results, recombinant SbpA as well as the rSbpA/Bet v1 fusion protein did not recrystallize in the E. coli cell cytoplasm . In view of the desired secretion of the SbpA/allergen fusion protein after expression in B. subtilis, in the present study, this fact turned out to be an advantage. As shown by electron microscopical investigation of thin sections of B. subtilis 1012 cells harvested 3h after induction of expression, no rSbpA/Bet v1 self-assembly products were visible in the cell cytoplasm of the host cells. Nearly 80% of rSbpA/Bet v1 secreted into the culture medium were soluble but electron microscopical investigation of B. subtilis culture samples taken 3 h after induction revealed that up to 20% of secreted fusion protein formed self-assembly products. According to results obtained by , no rSbpA/Bet v1 S-layer lattice could be observed on the cell surface of B. subtilis. However, for B. subtilis cells containing plasmid pHT01/sbpA/bet v1, just a weak intracellular expression of fusion protein could be observed. In order to increase the yield of expression, it could be conducive to replace the B. subtilis Pgrac promoter by one of the native sbpA promoters identified in the upstream region of the sbpA gene of Ly. sphaericus CCM 2177 in future studies.
Secreted rSbpA/Bet v1 could be concentrated by exploiting the specific interaction between the conserved N-terminus of SbpA in the fusion protein and a negatively charged pyruvylated SCWP which is located in the peptidoglycan-containing layer of Ly. sphaericus CCM 2177. In accordance to former studies performed with the S-layer/allergen fusion protein isolated from E. coli[14, 15], rSbpA/Bet v1 expressed and secreted by B. subtilis 1012 showed excellent recrystallization properties in suspension and on solid supports. By immunoblotting, the binding capacity of purified rSbpA/Bet v1 for IgE from serum samples of birch pollen allergic patients could be demonstrated.
In the present study for the first time, a pyrogen-free recombinant S-layer/allergen fusion protein required for vaccine development was produced using a gram-positive expression system based on B. subtilis 1012. The usage of an E. coli-B. subtilis shuttle vector carrying the sequence encoding the signal peptide of B. subtilis α-amylase confers on the gram-positive organism the ability to secrete the expressed S-layer/allergen fusion protein rSbpA/Bet v1 directly into the culture medium. Structural and immunological investigations of the obtained fusion protein revealed that rSbpA/Bet v1 was endotoxin-free, showed excellent recrystallization properties and immune reactivity.
Bacterial strains, plasmids and oligonucleotide primers
Bacterial strains, plasmids and oligonucleodide primers used in this study.
E. coli TG1
supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5(rK- mK-) [F' traD36 proAB lacIqZΔM15
B. subtilis 1012
leuA 8, metB 5, hsrM 1, nonA
CatchMaps BV, MoBiTec
Cloning of rsbpA/bet v1
Ampr, Cmr, Pgrac promoter (consisting of groEpromotor, the lacO operator and the gsiBSD sequence, ColE1 ori,, lacI repressor, E. coli/B. subtilis shuttle vector
see pHT01 + amyQ signal sequence
pHT01/sbpA/bet v 1
Expression of rSbpA/Bet v1 in cytoplasm of B. subtilis 1012
Expression of rSbpA/Bet v1 in cytoplasm of B. subtilis 1012 followed by subsequent secretion into the culture medium
Cloning of the chimaeric gene encoding rSbpA/Bet v1 in pHT01 and in pHT43
For amplification of the gene encoding the S-layer/allergen fusion protein rSbpA/Bet v1 (devoid of the sequence encoding the SbpA signal peptide), the plasmid pET28a (Invitrogen) carrying the chimaeric gene sbpA/bet v1 derived from a previous study  was isolated from E. coli TG1 and used as template. PCR amplifications were performed as described in . The oligonucleotide primer SbpA/AatII/forward as well as the primer Bet v1/SmaI/reverse (all listed in Table 1) introduced the cloning sites Aat II and Sma I at the 5' and 3'-end, respectively. General procedures for DNA manipulations were carried out as reported by . Cloning of pHT01 (MoBiTec) and pHT43 (MoBiTec) carrying the gene encoding rSbpA/Bet v1 in E. coli TG1 (Stratagene) was done as described in . For selection of positive transformants, the constructs were grown in 3 ml Luria-Broth Base medium (Invitrogen) at 37°C and carbenicillin (Fluka) was added to a final concentration of 50 μg/ml. Finally, plasmids pHT01/sbpA/bet v1 and pHT43/sbpA/bet v1 were re-isolated from E. coli TG1 by using QIAprep Spin Miniprep Kit (Qiagen) and stored at -20°C. The correct construction of the vectors was confirmed by sequencing.
Preparation of competent B. subtilis 1012 cells
B. subtilis 1012 (CatchMaps BV) was grown overnight at 37°C in a test tube on 5 ml HS medium (66.5 ml A. dest., 10 ml 10 × S-base (Spizizen's salt), 2.5 ml 20% (w/v) glucose, 5 ml 0.1% (w/v) L-tryptophan, 1 ml 2% (w/v) casein, 5 ml 10% (w/v) yeast extract (Difco), 10 ml 8% (w/v) arginine, 0.4% histidine) under shaking at 200 rpm. Subsequently, 0.5 ml of the overnight culture were diluted in 50 ml HS medium in a 500-ml flask, incubated under shaking at 200 rpm at 37°C and the growth curve was recorded. When cells reached the stationary growth phase, samples of 10 ml were taken at 15-min time intervals. Each aliquot was mixed with 1 ml 87% glycerol and incubated for 15 min on ice. After fractionating into 1-ml aliquots, all samples were frozen in liquid nitrogen and stored at -80°C. For estimation of the aliquots yielding high level competent cells, one aliquot from each point in time was checked by transformation with a reference plasmid pHT43 (MoBiTec) without insert.
Transformation of B. subtilis 1012
For transformation of B. subtilis 1012, the slightly modified protocol of  was used. Cryo cultures of competent B. subtilis 1012 cells were thawed at 37°C, one aliquot (1 ml) was used to inoculate 20 ml HS medium and the culture was shaken at 200 rpm in a 30°C-water bath for 2 h. Aliquots of 1 ml were put into a glass tube, 10 μl of 0.1 M EGTA, pH 7.2 were added and the mixture was incubated for 5 min at room temperature. Plasmid DNA (3 μg) pHT01/sbpA/bet v 1 or pHT43/sbpA/bet v1, respectively, was added and the sample was incubated for 2 h at 37°C while shaking at 200 rpm. For detection of positive B. subtilis transformants, cells were plated on selective LB plates containing chloramphenicol at a final concentration of 10 μg/ml.
Expression of the S-layer/allergen fusion protein in B. subtilis 1012, preparation of cellular and supernatant fractions and immunoblot analysis
B. subtilis 1012 cells carrying the plasmids pHT01/sbpA/bet v 1 or pHT43/sbpA/bet v1, respectively, were grown in 3 ml LB medium containing chloramphenicol at a final concentration of 10 μg/ml in a test tube under shaking at 200 rpm at 37°C overnight. Subsequently, 25 ml LB medium were inoculated with 250 μl of the culture (dilution 1:100) containing chloramphenicol at a final concentration of 10 μg/ml and incubated under shaking at 200 rpm at 37°C. At an optical density of 2 at 600 nm, expression of rSbpA/Bet v1 was induced by addition of IPTG at a final concentration of 1 mM. Samples (1.5 ml) of each B. subtilis 1012 culture were taken before as well as 1 h, 2 h, 3 h and 18 h after induction of expression of rSbpA/Bet v1. The supernatant and cellular fractions were separated by centrifugation at 20,000 × g for 30 min at 4°C. Cell pellets were incubated with lysozyme (final concentration 1 mg/ml) for 5 min at 37°C before addition of Laemmli buffer . Preparation of samples for SDS-PAGE analysis was carried out as described by .
Immunoblotting with a polyclonal rabbit antiserum raised against the S-layer protein SbpA of Ly. sphaericus CCM 2177 was performed as described previously . The monoclonal mouse anti-Bet v1 antibody BIP1 was used to check to presence of Bet v1 epitopes in the fusion protein rSbpA/Bet v1 expressed in B. subtilis 1012 as well as in the fusion protein rSbpA/Bet v1 expressed in E. coli (derived from a former study ), which was used as a positive control. For that purpose, after separation of the proteins on SDS gels and blotting to a nitrocellulose membrane (Potran; Schleicher and Schüll), blocking with 0.2% (Blocking Reagent CA AppliChem, Germany) in Tris-buffered saline solution (0.1 M TBS, pH 7.2) was applied for 18 h at 4°C. The membrane was then incubated with BIP1 (diluted 1:100 in blocking solution) for 1.5 h at room temperature and washed three times with wash solution (0.1 M TBS containing 0.5% Tween20) and once with 0.1 M TBS. Subsequently, the membrane was incubated with anti-mouse IgG alkaline phosphatase conjugate (Sigma; diluted 1:5,000 in blocking solution) for 1 h at room temperature. After washing steps as described above, bound antibody was detected by incubation with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium chloride (BCIP/NBT; Roche) as precipitating chromogenic substrate.
Electron microscopical investigation of B. subtilis 1012 cells after expression and secretion of the S-layer/allergen fusion protein
For electron microscopical examination of B. subtilis 1012 cells containing pHT43/sbpA/bet v1 harvested 3 h after induction of expression, 30 μl of cell culture were transferred onto a 300-mesh Formvar-coated copper grid which was stabilized by vacuum deposition of carbon and rendered hydrophilic by glow discharge . For chemical fixation of the sample, the grid was floated on a drop of 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.0 for 15 min at room temperature. After 3 washing steps with distilled water, negative staining was done by incubation of the grid on a drop of 1% uranyl acetate for 5 min at room temperature . Fixation, embedding as well as ultrathin-sectioning of B. subtilis 1012 cells harvested 3 h after induction of rsbpA/bet v1 expression was performed as described in a previous study. Electron micrographs were taken with a Philips CM12 transmission electron microscope (Philips Eindhoven, The Netherlands) operated at 80 kV in low-dose mode .
Peparation of peptidoglycan-containing sacculi of Ly. sphaericus CCM 2177
Ly. sphaericus CCM 2177 (Czech Collection of Microorganism, Brno, Czech Republic) was grown in continuous culture in nutrient broth medium at 30°C at a dilution rate of 0.16 h-1 as described in a previous study . Preparation of cell wall fragments of Ly. sphaericus CCM 2177 was done according to . For preparation of peptidoglycan-containing sacculi, cell wall fragments of Ly. sphaericus CCM 2177 were incubated twice with 5 M guanidine hydrochloride (GHCl) in 50 mM Tris/HCl, pH 7.2 for 20 min at 4°C for complete removal of the wild-type S-layer protein SbpA. Subsequently, the remaining peptidoglycan pellet was washed four times with 50 mM Tris/HCl, pH 7.2, suspended in 15 ml of distilled water, frozen at -20°C, and lyophilized.
Purification and concentration of the fusion protein rSbpA/Bet v1 by recrystallization on solid supports, immunogold-labelling and investigation by electron microscopy
For isolation and concentration of the secreted fusion protein rSbpA/Bet v1, 3 h after induction of expression, 1 mg lyophilized peptidoglycan-containing sacculi of Ly. sphaericus CCM 2177 were added to a 5-ml aliquot of the B. subtilis 1012/pHT43/sbpA/bet v1 culture supernatant. To induce the recrystallization process of the fusion protein on the surface, the mixture was adjusted to 10 mM CaCl2 and incubated by shaking at 4°C overnight. Subsequently, the suspension was centrifuged at 20,000 × g at 4°C for 10 min and the pellet was incubated again with a new 5-ml aliquot of supernatant of the B. subtilis 1012/pHT43/sbpA/bet v1 culture. The procedure was repeated 2 times and the pellet containing recrystallization products was subsequently applied for negative staining and electron microscopical investigation performed as described above.
Immunogold-labelling was done by incubation of the samples with monoclonal mouse antibody BIP1 raised against Bet v1 for 2 h at room temperature. After centrifugation of the suspension at 16,000 × g for 10 min at 4°C and 3 washing steps with 0.15 M TBS buffer, the pellet was suspended in 30 μl anti-mouse IgG-colloidal gold (Sigma) and incubated for 60 min at room temperature. Unbound gold-labelled antibody was removed by centrifugation under conditions described above and three washing steps with 0.15 M TBS buffer. The pellet was resuspended in 20 μl distilled water and subjected to negative staining. As a control, the whole procedure was also performed by using recrystallization products consisting of rSbpA (recombinantly produced in E. coli in a previous study  which was recrystallized on peptidoglycan-containing sacculi of Ly. sphaericus CCM 2177.
Quantification of the amount of purified rSbpA/Bet v1 after extracelluar expression by B. subtilis 1012
For quantification of expression, recrystallization products (produced as described above) consisting of rSbpA/Bet v1 (derived from 20 ml culture supernatant) recrystallized on 1 mg peptidoglycan-containing sacculi of Ly. sphaericus CCM 2177 were incubated with 2 ml of 5 M GHCl in 50 mM Tris/HCl, pH 7.2 for 10 min at 4°C. The fusion protein rSbpA/Bet v1 was separated from the peptidoglycan-containing sacculi of Ly. sphaericus CCM 2177 by centrifugation of the samples at 14,000 rpm for 15 min at 4°C. The supernatant was dialyzed against distilled water for 16 h at 4°C and 10 μl were subjected to SDS-PAGE analysis. To estimate the concentration of the fusion protein in the dialyzed supernatant, 10 μl of a 1 mg/ml stock solution (10 μg) of rSbpA/Bet v1 purified from E. coli was also subjected to the SDS-PAGE and used as a reference.
Immuno dot blot for detection of IgE reactivity of rSbpA/Bet v1 by with serum samples from birch pollen allergic patients
For investigation of IgE reactivity, rSbpA/Bet v1 fusion protein as well as rSbpA acting as blank and rBet v1 used as positive control (both proteins derived from ) were spotted onto a nitrocellulose membrane which was subsequently incubated with sera from patients suffering from birch pollen allergy at 4°C for 16 h. The procedure was followed by incubation with monoclonal anti-human IgE alkaline phosphatase conjugate (Sigma; diluted 1:6,000) and detection with BCIP/NBT was done as described above.
Biocompatibility test for investigation of LAL reactivity of rSbpA/Bet v1 expressed in B. subtilis 1012
Detection and quantification of gram-negative bacterial endotoxins of 100 μl culture medium containing rSbpA/Bet v1 secreted by B. subtilis 1012 during 3 h of expression was performed following the manufacturer's instructions (Limulus Amebocyte Lysate, PYROCHROME®, U.S.). Results were compared with those obtained from LAL-tests carried out with rSbpA/Bet v1 which was expressed in E. coli BL21Star(DE3) (Invitrogen) and purified as described in a former study .
This work was supported by the FP6 EC-STREP project NASSAP 13523, by the Austrian Science Fund (FWF) Project P18510-B12 as well as by the US Air Force Office of Scientific Research (AFOSR) projects FA9550-07-1-0313 and FA9550-10-1-0223. We thank the company CatchMabs BV (Wageningen, The Netherlands) for providing strain Bacillus subtilis 1012.
- Sleytr UB, Beveridge TJ: Bacterial S-layers. Trends Microbiol. 1999, 7 (6): 253-260. 10.1016/S0966-842X(99)01513-9.View ArticleGoogle Scholar
- Sleytr UB, Messner P: Crystalline bacterial cell surface layers (S-layers). Encyclopedia of Microbiology. Edited by: Schaechter M. 2010, San Diego: Elsevier Science, 1: 89-98. 3Google Scholar
- Sleytr UB, Sára M, Pum D, Schuster B, Messner P, Schäffer C: Self-assembly protein systems: microbial S-layers. Biopolymers. Edited by: Steinbüchel A, Fahnestock S. 2003, Weinheim: Wiley-VCH, 7: 285-338.Google Scholar
- Ilk N, Egelseer EM, Ferner-Ortner J, Küpcü S, Pum D, Schuster B, Sleytr UB: Surfaces functionalized with self-assembling S-layer fusion proteins for nanobiotechnological applications. Colloides and Surfaces A: Physicochem and Eng Aspects. 2007, 321: 163-167. 10.1016/j.colsurfa.2007.12.038.View ArticleGoogle Scholar
- Sleytr UB, Egelseer E, Ilk N, Pum D, Schuster B: S-Layers as a basic building block in a molecular construction kit. FEBS J. 2007, 274: 323-334. 10.1111/j.1742-4658.2006.05606.x.View ArticleGoogle Scholar
- Sleytr UB, Huber C, Ilk N, Pum D, Schuster B, Egelseer E: S-Layers as a tool kit for nanobiotechnological applications. FEMS Microbiol Lett. 2007, 267: 131-144. 10.1111/j.1574-6968.2006.00573.x.View ArticleGoogle Scholar
- Ilk N, Kosma P, Puchberger M, Egelseer EM, Mayer HF, Sleytr UB, Sára M: Structural and functional analyses of the secondary cell wall polymer of Bacillus sphaericus CCM 2177 that serves as an S-layer-specific anchor. J Bacteriol. 1999, 181 (24): 7643-7646.Google Scholar
- Mader C, Huber C, Moll D, Sleytr UB, Sára M: Interaction of the crystalline bacterial cell surface layer protein SbsB and the secondary cell wall polymer of Geobacillus stearothermophilus PV72 assessed by real-time surface plasmon resonance biosensor technology. J Bacteriol. 2004, 186 (6): 1758-1768. 10.1128/JB.186.6.1758-1768.2004.View ArticleGoogle Scholar
- Ries W, Hotzy C, Schocher I, Sleytr UB, Sára M: Evidence that the N-terminal part of the S-layer protein from Bacillus stearothermophilus PV72/p2 recognizes a secondary cell wall polymer. J Bacteriol. 1997, 179 (12): 3892-3898.Google Scholar
- Schäffer C, Messner P: The structure of secondary cell wall polymers: how Gram-positive bacteria stick their cell walls together. Microbiology. 2005, 151 (Pt 3): 643-651.View ArticleGoogle Scholar
- Sleytr UB, Egelseer EM, Ilk N, Messner P, Schäffer C, Pum D, Schuster B: Nanobiotechnological applications of S-layers. Prokaryotic Cell Wall Compounds - Structure and Biochemistry. Edited by: König H, Claus H, Varma A. 2010, Heidelberg, Germany: Springer, 459-481. full_text.View ArticleGoogle Scholar
- Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, Creticos PJ, Dayer JM, Durham SR, Demloy P: Allergen immunotherapy: therapeitic vaccines for allergic diseases: World Health Organization: American Academy of Allergy, Asthma and Immunology. AnnAllergy Asthma Immunol. 1998, 81: 401-10.1016/S1081-1206(10)63136-5.View ArticleGoogle Scholar
- Bohle B, Breitwieser A, Zwölfer B, Jahn-Schmid B, Sára M, Sleytr UB, Ebner C: A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol. 2004, 172 (11): 6642-6648.View ArticleGoogle Scholar
- Breitwieser A, Egelseer EM, Moll D, Ilk N, Hotzy C, Bohle B, Ebner C, Sleytr UB, Sára M: A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured monomolecular lattices and the functionality of the allergen. Protein Eng. 2002, 15 (3): 243-249. 10.1093/protein/15.3.243.View ArticleGoogle Scholar
- Ilk N, Völlenkle C, Egelseer EM, Breitwieser A, Sleytr UB, Sára M: Molecular characterization of the S-layer gene, sbpA, of Bacillus sphaericus CCM 2177 and production of a functional S-layer fusion protein with the ability to recrystallize in a defined orientation while presenting the fused allergen. Appl Environ Microbiol. 2002, 68 (7): 3251-3260. 10.1128/AEM.68.7.3251-3260.2002.View ArticleGoogle Scholar
- Gerstmayr M, Ilk N, Jahn-Schmid B, Sleytr UB, Bohle B: Natural self-assembly of allergen-S-layer fusion proteins is no prerequisite for reduced allergenicity and T cell stimulatory capacity. Int Arch Allergy Immunol. 2009, 149 (3): 231-238. 10.1159/000199718.View ArticleGoogle Scholar
- Gerstmayr M, Ilk N, Schabussova I, Jahn-Schmid B, Egelseer EM, Sleytr UB, Ebner C, Bohle B: A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J Immunol. 2007, 179 (11): 7270-7275.View ArticleGoogle Scholar
- Magalhaes PO, M LA, G MP, Rangel-Yagui CR, Penna TCV, Pessoa A: Methods of endotoxin removal from biological preparation: a Review. J Pharmaceut Sci. 2007, 10 (3): 388-404.Google Scholar
- Westers L, Westers H, Quax WJ: Bacillus subtilis as cell factory for pharmaceutical proteins: a biotechnological approach to optimize the host organism. Biochim Biophys Acta. 2004, 1694 (1-3): 299-310. 10.1016/j.bbamcr.2004.02.011.View ArticleGoogle Scholar
- Fu LL, Xu ZR, Li WF, Shuai JB, Lu P, Hu CX: Protein secretion pathways in Bacillus subtilis: Implication for optimization of heterologous protein secretion. Biotechnology Advances. 2006, 25: 1-12.Google Scholar
- Wong SL: Advances in the use of Bacillus subtilis for the expression and secretion of heterologous proteins. Curr Opin Biotechnol. 1995, 6 (5): 517-522. 10.1016/0958-1669(95)80085-9.View ArticleGoogle Scholar
- Magalhaes PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TC, Pessoa A: Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci. 2007, 10 (3): 388-404.Google Scholar
- Sweadner KJ, Forte M, Nelsen LL: Filtration removal of endotoxin (pyrogens) in solution in different states of aggregation. Appl Environ Microbiol. 1977, 34 (4): 382-385.Google Scholar
- Shibatani T, Kakimoto T, Chibata I: Purification of high molecular weight urokinase from human urine and comparative study of two active forms of urokinase. Thromb Haemost. 1983, 49 (2): 91-95.Google Scholar
- Issekutz AC: Removal of gram-negative endotoxin from solutions by affinity chromatography. J Immunol Methods. 1983, 61 (3): 275-281. 10.1016/0022-1759(83)90221-1.View ArticleGoogle Scholar
- Sleytr UB, Messner P, Pum D, Sára M: Crystalline bacterial cell surface layers (S-layers): from supramolecular cell structure to biomimetics and nanotechnology. Angew Chem Int Ed. 1999, 38: 1034-1054. 10.1002/(SICI)1521-3773(19990419)38:8<1034::AID-ANIE1034>3.0.CO;2-#.View ArticleGoogle Scholar
- Simonen M, Palva I: Protein secretion in Bacillus species. Microbiol Rev. 1993, 57 (1): 109-137.Google Scholar
- Howorka S, Sára M, Lubitz W, Kuen B: Self-assembly product formation of the Bacillus stearothermophilus PV72/p6 S-layer protein SbsA in the course of autolysis of Bacillus subtilis. FEMS Microbiol Lett. 1999, 172 (2): 187-196. 10.1111/j.1574-6968.1999.tb13468.x.View ArticleGoogle Scholar
- Jarosch M, Egelseer EM, Huber C, Moll D, Mattanovich D, Sleytr UB, Sára M: Analysis of the structure-function relationship of the S-layer protein SbsC of Bacillus stearothermophilus ATCC 12980 by producing truncated forms. Microbiology. 2001, 147 (Pt 5): 1353-1363.View ArticleGoogle Scholar
- Kuen B, Koch A, Asenbauer E, Sára M, Lubitz W: Molecular characterization of the Bacillus stearothermophilus PV72 S-layer gene sbsB induced by oxidative stress. J Bacteriol. 1997, 179 (5): 1664-1670.Google Scholar
- Kuen B, Sára M, Lubitz W: Heterologous expression and self-assembly of the S-layer protein SbsA of Bacillus stearothermophilus in Escherichia coli. Mol Microbiol. 1996, 19 (3): 495-503. 10.1046/j.1365-2958.1996.386918.x.View ArticleGoogle Scholar
- Jarosch M, Egelseer EM, Mattanovich D, Sleytr UB, Sára M: S-layer gene sbsC of Bacillus stearothermophilus ATCC 12980: molecular characterization and heterologous expression in Escherichia coli. Microbiology. 2000, 146 (Pt 2): 273-281.View ArticleGoogle Scholar
- Sambrook JFEF, Maniatis T: Molecular cloning: a laboratory manual. 1989, N.Y.: Cold Spring Habour Laboratory Press, 2Google Scholar
- Anagnostopoulos C, Spizizen J: Requirements for transformation in Bacillus subtilis. J Bacteriol. 1961, 81 (5): 741-746.Google Scholar
- Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0.View ArticleGoogle Scholar
- Pum D, Sára M, Sleytr UB: Structure, surface charge, and self-assembly of the S-layer lattice from Bacillus coagulans E38-66. J Bacteriol. 1989, 171 (10): 5296-5303.Google Scholar
- Egelseer EM, Leitner K, Jarosch M, Hotzy C, Zayni S, Sleytr UB, Sára M: The S-layer proteins of two Bacillus stearothermophilus wild-type strains are bound via their N-terminal region to a secondary cell wall polymer of identical chemical composition. J Bacteriol. 1998, 180 (6): 1488-1495.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.